Entry Point Capital, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 11,666 shares of CPRX stock, worth $245,102. This represents 0.13% of its overall portfolio holdings.
Number of Shares
11,666
Previous 12,115
3.71%
Holding current value
$245,102
Previous $293,000
13.65%
% of portfolio
0.13%
Previous 0.14%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$393 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$115 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$68.3 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...